review of fluvoxamine safety database
Post on 18-Mar-2017
Embed Size (px)
Drugs 43 (Suppl, 2): 48-54. 19920012-6667/92/0200-0048/$3.50/0 Adis International Limited. All rights reserved.
Review of Fluvoxamine Safety Database
W. Wagner, I B. Plekkenpol, I T.E. Gray, I H. Vlaskamp2 and H. Essers-I Solvay Pharmaceuticals Inc., Marietta, Georgia, USA2 Solvay Duphar B.V., Weesp, The Netherlands
Summary A review of the safety and tolerability of fluvoxamine in worldwide marketing studies in-volving 24 624 patients, predominantly receiving fluvoxamine treatment in uncontrolled studiesin depression, has been conducted. There was a marked preponderance of female patients andpatients aged between 30 and 50 years. The majority of patients were treated for 6 weeks, withthe most frequent modal total daily dose being 100mg. The greatest proportion of adverse ex-periences occurring, by COSTART body system, affected the digestive system (24.1%), the nerv-ous system (23.7%), and the body as a whole (15.3%). The only adverse experience with anincidence greater than 10%was nausea (15.7%), with somnolence (6.9%) and asthenia (6.2%) asthe next most frequent experiences. Notably, the rates of agitation and anxiety were only 1.4 and1.3%, respectively. The incidences of adverse experiences increased with age, and were slightlyhigher in females than males. 15.1% of patients discontinued treatment prematurely as a resultof adverse experiences, principally nausea, dizziness, vomiting, somnolence, abdominal pain, andheadache. The overall incidence of serious adverse events associated with fluvoxamine treatmentwas 2.5%, and the incidence of overall suicidality, including suicidal ideation, overdose, andintentional overdose as well as attempted and completed acts of suicide, was remarkably low at0.8%.
We have conducted a review of the safety andtolerability of fluvoxamine in marketing studiesworldwide, the main results of which are here pre-sented publicly for the first time. The data assem-bled represent probably the largest aggregate of in-formation regarding safety ever amassed andpublished for any antidepressant drug.
The data were analysed by a multinational taskforce assisted by 6 contract research organisations,with the entire review and data management beingcompleted in 13 months. In total, 25372 originalcase record forms in 7 languages were collected and
subjected to a medical review, to provide the re-quisite degree of rigour and consistency in the eval-uation of the safety profile. Subsequently, 4069narrative patient summaries were written and laterstored on an optical laser disc imaging system; allsafety data were double entered into intermediatedatabases that reflected the layout ofthe study caserecord form, then transferred into a standard in-dividual study database format, and finally mergedinto one global safety database. The data manage-ment and the analysis were conducted and moni-tored according to Good Clinical Practice (GCP)guidelines, and employed the US Food and DrugAdministration (FDA) criteria for defining 'seri-ous' adverse events.
Fluvoxamine Safety Database
2. Overview ofStudies
Table III. Demographic characteristics of the 24624 patients
treated with fluvoxamine
other indications (table II). Dosages employedranged from 50 to 300mg per day, while the dur-ation ofthe studies varied between 4 and 52 weeks.
As table I indicates, the majority of studies,namely 43, were conducted in depression, with 10trials in a variety of other indications, such as painstates, anxiety disorders, alcoholism etc., and 1 trialin obsessive-compulsive disorder. In total, 54 stud-ies were analysed, with 53 originating in Europeand I in Pakistan.
3. Exposure to Fluvoxamine
The total cohort receiving fluvoxamine for whichdata have been reviewed and analysed is 24 624patients. By far the greatest number of patients, ap-proximately 23 500, received fluvoxamine in un-controlled studies in depression, with only a verysmall proportion of patients treated with fluvox-amine in controlled studies in depression and in
No data available
No data available
% of patients
Table II. Exposure to f1uvoxamine by indication
Table I. Overview of 54 studies
No. of studies
No. of patients
4. Patient Demographic Characteristics
There was a marked predominance of femalepatients, approximately 70%, in accordance withthe general epidemiological distribution of the dis-order, and the largest proportion of patients wereaged between 30 and 50 years (table III). The sexand age distribution of patients was similar acrossstudies.
5. Duration of Treatment
Table IV indicates that a considerable numberof patients - 11 428 - were treated for 6 weeks,almost all of these in uncontrolled studies indepression. This reflects the conventional design ofmarketing studies with antidepressants. The sex andage distribution of patients was similar across therespective duration intervals.
For all dose parameters - the modal, maximum,and mean total daily doses - the distribution ofdosages was similar across studies, and the sex andage distribution of patients was not significantlydifferent across dose ranges.
50 Drugs 43 (Suppl. 2) /992
a 98% in uncontrolled studies in depression.
The modal total daily dose represents the mostcommon or frequent dose offluvoxamine that wasmaintained during the patient's participation in thestudy. It reflects the attainment of a balance be-tween clinical efficacy and the occurrence of un-desired secondary effects. The majority of patientsreceived a relatively low modal total daily dose of100mg (46%) or 150mg (16%).
The maximum total daily dose is defined as thehighest dose ever prescribed for a single patient forat least I day. The maximum total daily dose wassimilarly low in the majority of patients, at 100mg(45%), 150mg (18%), or 200mg (14%).
The mean total daily dose of fluvoxamine (thesum of each dose level attained by the patient,multiplied by the number of days at that level, di-vided by the total duration of treatment in days)ranged between 100 and 150mg in 48% of patientsexposed. In terms ofthis safety review, we considerthe mean total daily dose to be a less reliable para-meter, since in essentially all studies, an initial ti-tration phase was involved, which would tend tomove the mean dose downwards relative to themaintenance dose at which patients were stabilised- i.e. this parameter tends to underestimate the truemean dose of maintenance therapy.
In terms of the relationship between dose andduration of treatment, the maintenance modal daily
a Denominator adjusted for gender-specific symptoms.
7. Adverse Drug Experiences
Body as a whole
Table V. Adverse experiences in the 24624 patients treated
with fluvoxamine, by COSTART body system
Adverse experiences were analysed employingthe most conservative approach based on FDA reg-ulations, i.e. no causality judgements were madebut all recorded events were regarded as advers~experiences; where some uncertainty existed, the'worst case scenario' for the drug was applied.Table V enumerates adverse experiences by CO-START body system, and indicates that the great-est proportion of adverse experiences occurringaffected the digestive system (24.1%), the nervoussystem (23.7%), and the body as a whole (15.3%).
Table VI lists the overall incidence of adverseexperiences. The only symptom that may be de-scribed as 'common', i.e. it occurred with an in-cidence of greater than 10%, was nausea (15.7%).The incidence of all other adverse experiences wasless than 10%; of these, somnolence (6.9%) and as-thenia (6.2%) were the next most frequent symp-
dose for 8 weeks' treatment or more was 100 to150mg in 71%of patients, and it is noteworthy thatthis is a rather low dose range. Finally, the maxi-mum total daily dose increased with increasingduration of treatment, reflecting the design of moststudies, which included a titration phase; a similarpattern was observed for the mean total daily dose.
No. of patients
Treatment duration (weeks)
'" 104No data available
Table IV. Duration of fluvoxamine treatment
Fluvoxamine Safety Database 51
Table VI. Overall incidence of adverse experiences in the 24624patients treated with fluvoxamine
toms. It is noteworthy that agitation and anxietyare represented at very low incidences of 1.4 and1.3%, respectively. This is in marked contrast tothe adverse experience profile of other serotoninreuptake inhibitors.
The overall incidence of adverse experienceswasobserved to increase with age, and the highest rateswer